<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16553">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01801709</url>
  </required_header>
  <id_info>
    <org_study_id>C11-09</org_study_id>
    <secondary_id>2011-004410-42</secondary_id>
    <nct_id>NCT01801709</nct_id>
  </id_info>
  <brief_title>Intracerebral Gene Therapy for Children With Early Onset Forms of Metachromatic Leukodystrophy</brief_title>
  <acronym>TG-MLD</acronym>
  <official_title>A Phase I/II, Open Labeled, Monocentric Study of Direct Intracranial Administration of a Replication Deficient Adeno-associated Virus Gene Transfer Vector Serotype rh.10 Expressing the Human ARSA cDNA to Children With Metachromatic Leukodystrophy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Leukodystrophy Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this open-label, single arm, monocentric, phase I/II clinical study is to
      assess safety and efficacy of ARSA gene transfer in the brain of children affected with
      early onset forms of Metachromatic Leukodystrophy (MLD). For this purpose, an
      adeno-associated virus serotype rh.10 (AAVrh.10) vector will be used to transfer the ARSA
      cDNA coding for Arylsulfatase A (ARSA) enzyme into the brain of children. Five patients with
      early onset form of MLD, age ranging from 6 months to 4 years, will be included in this
      protocol and will be followed during 24 months.

      Patients will be selected at presymptomatic or early stage of their disease, following
      clinical, neuropsychological and brain imaging criteria.

      Twelve simultaneous injections of the investigational medicinal product will be performed in
      the white matter of both brain hemispheres, through 6 image-guided tracks, with 2 deposits
      per track.

      A low dose (1x10EXP12 vg total) will be administered to the first 2 patients, while the last
      3 will receive a higher dose (4x10EXP12 vg total).

      Safety and efficiency will be evaluated based on clinical, neuropsychological, radiological,
      electrophysiological and biological parameters.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Evaluate the tolerance of the intracerebral administration of a single dose of AAVrh.10cuARSA</measure>
    <time_frame>During the two years follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Tolerance will be measured by :
Adverse event,
Clinical and neurological exams,
Laboratory tests,
Neuroimagery (CT scan, brain MRI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy of intracerebral administration of a single dose of AAVrh.10cuARSA to stop the disease progression.</measure>
    <time_frame>During the two years follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy will be measured by:
MLD neurological severity score,
Neurological evaluation,
Motor scores (GMFM, Ashworth and ICARS),
Cognitive functions (Bayley Scales of Infant Development (BSID)(0-42 months), or Wechsler Preschool and Primary Scale of Intelligence-III (WPPSI-III) (43 months-6 years)),
MLD severity MRI score, MRI-DTI parameters, measurement of cerebral atrophy and spectroscopy,
Neuroelectrophysiological tests (peripheral nerve conduction velocity, visual, auditory and somatosensory evoked potentials).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Metachromatic Leukodystrophy</condition>
  <arm_group>
    <arm_group_label>AAVrh.10cuARSA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intracerebral administration of AAVrh.10cuARSA at 12 sites in the white matter of both brain hemispheres.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>intracerebral administration of AAVrh.10cuARSA</intervention_name>
    <arm_group_label>AAVrh.10cuARSA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Boys or girls with an early onset form of MLD.

          -  Age between 6 months and 5 years, inclusive

          -  Diagnostic of MLD based on the measurement of ARSA activity in leukocytes and the
             accumulation of sulfatides in urine, along with normal activity of at least one other
             sulfatase

          -  Informed consent signed up and willingness for monitoring 2 years after treatment.

          -  Normal values for standard laboratory tests

        Exclusion Criteria:

          -  Absence of ARSA protein by immunocytochemistry and/or ELISA

          -  Gestational age &lt;32 weeks of amenorrhoea and age &lt; 1 year

          -  Brain atrophy with a subdural space &gt; 10 mm in the frontal region

          -  Performance IQ&lt;50 at WPPSI-III or cognitive function &lt; 3rd percentile at the Bayley's
             test of infant development

          -  If age &gt; 16 months at inclusion, inability to walk few steps alone OR inability to
             walk few steps with support on one side along with inability to stand up alone

          -  Impossibility for anesthesia

          -  Malignancy, cardiac malformation, liver dysfunction, or renal dysfunction

          -  Neurological disorder, except benign, not related to MLD.

          -  Any other clinically significant untreated co-morbid medical condition as determined
             by the clinical investigator, including cardiac, pulmonary or kidney disease.

          -  MRI impossibility

          -  Evoked potential impossibility

          -  Participation to another therapeutic clinical trial for MLD.

          -  Unaffiliated to any French or any other National Health Insurance.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Aubourg, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris and Institut National de la Santé et de la Recherche Médicale</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Caroline Sevin, MD-PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Zerah, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Roujeau, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathalie Cartier, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut National de la Santé et de la Recherche Biomédicale</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Aubourg, MD - PhD</last_name>
    <phone>33.1 4959 5396</phone>
    <email>patrick.aubourg@inserm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline Sevin, MD - PhD</last_name>
    <phone>33.1 4521 3017</phone>
    <email>caroline.sevin@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bicêtre Hospital - Paris Sud</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Aubourg</last_name>
      <email>patrick.aubourg@inserm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Caroline Sevin</last_name>
      <email>caroline.sevin@inserm.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick Aubourg</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Sevin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Piguet F, Sondhi D, Piraud M, Fouquet F, Hackett NR, Ahouansou O, Vanier MT, Bieche I, Aubourg P, Crystal RG, Cartier N, Sevin C. Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice. Hum Gene Ther. 2012 Aug;23(8):903-14. doi: 10.1089/hum.2012.015. Epub 2012 Jul 23.</citation>
    <PMID>22642214</PMID>
  </reference>
  <reference>
    <citation>Sondhi D, Johnson L, Purpura K, Monette S, Souweidane MM, Kaplitt MG, Kosofsky B, Yohay K, Ballon D, Dyke J, Kaminksy SM, Hackett NR, Crystal RG. Long-Term Expression and Safety of Administration of AAVrh.10hCLN2 to the Brain of Rats and Nonhuman Primates for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis. Hum Gene Ther Methods. 2012 Oct;23(5):324-35. doi: 10.1089/hgtb.2012.120. Epub 2012 Nov 6.</citation>
    <PMID>23131032</PMID>
  </reference>
  <reference>
    <citation>Colle MA, Piguet F, Bertrand L, Raoul S, Bieche I, Dubreil L, Sloothaak D, Bouquet C, Moullier P, Aubourg P, Cherel Y, Cartier N, Sevin C. Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. Hum Mol Genet. 2010 Jan 1;19(1):147-58. doi: 10.1093/hmg/ddp475. Epub .</citation>
    <PMID>19837699</PMID>
  </reference>
  <reference>
    <citation>i Dali C, Hanson LG, Barton NW, Fogh J, Nair N, Lund AM. Brain N-acetylaspartate levels correlate with motor function in metachromatic leukodystrophy. Neurology. 2010 Nov 23;75(21):1896-903. doi: 10.1212/WNL.0b013e3181feb217.</citation>
    <PMID>21098404</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>January 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain Gene Therapy</keyword>
  <keyword>Adeno Associated vector</keyword>
  <keyword>Lysosomal sotage diseases</keyword>
  <keyword>Leukodystrophies</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukodystrophy, Metachromatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
